Trial Site Detail

 

Drug:
CB-839 + Talazoparib
Trial:
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Conditions: Solid Tumors
Trial Status:
Terminated

 

University of Iowa Hospitals and Clinics

     
Iowa City , IA 52242
USA

 

Principal Investigator:
 Yousef Xakharia, MD
Contact:
 Heidi Haugland 319-384-5285 heidi-haugland@uiowa.edu
Activation Status of this Site:
 Closed
Notes about this Site:
University of Iowa Hospitals and Clinics Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.